Down Syndrome : Cardinal Features, Screening Recommendations
Last Updated : 8/1/2015
Swati Kolpuru
Cardinal features in neonates
- Poor Moro reflex (85%)
- Hypotonia (80%)
- Flat facial profile (90%)
- Upslanted palpebral fissures (80%)
- Abnormal ears (60%)
- Excess skin on the back of neck (80%)
- Transverse palmar crease (45%)
- Hyperextensible joints (80%)
- Dysplasia of pelvis (70%)
- Fifth finger clinodactyly (60%)
Six or more of the above features should be present for making a diagnosis clinically. Sometimes the findings may be subtle and may be missed. Also the findings can be confounded by prematurity or ethnicity.

- Establish diagnosis
- Thorough clinical examination to observe for congenital heart disease or gastrointestinal malformation
- Inform the parents in a supportive way

Laboratory orders:
- Chromosomal karyotype
- Thyroxine
- Complete blood count
- Differential count
- Platelet count
- Nucleated RBC count
- Echocardiography
- Hearing screen
- Funduscopy
Discuss diagnosis and management plan with parents. Refer parents to an infant intervention program and to a support group. Conduct a follow-up meeting with family

Screening Recommendations
Neonatal period (Birth to one month):
- Chromosomal karyotype
- Hematocrit or complete blood count to rule out myeloproliferative disorders
- Thyroid function tests
- Echocardiogram
- Auditory brainstem response or otoacoustic emission test to assess congenital sensorineural hearing at birth or by 3 months of age.
- Ophthalmologic evaluation if nystagmus or strabismus

Infancy (1-12 months):
- Echocardiogram if not done in newborn period
- Auditory brainstem response test if previous results are suspicious.
- Ophthalmologic evaluation by six months of age.
- Thyroid function test at 6 and 12 months of age.

Childhood (1 year to 12 years):
- Echocardiogram if not done previously.
- Thyroid function test yearly.
- Regular eye exams yearly if normal, or more frequently as indicated.
- Between 3 and 5 years of age, lateral cervical spine x-rays to rule out atlanto-axial instability.
- Dental evaluation at one year of age and follow-ups every six months.
- Celiac disease screening with IgA antiendomysium antibodies and total IgA at 2-3 years of age.

Adolescence (12 to 18 years):
- Pelvic exam if sexually active.
- Thyroid function testing yearly.
- Hearing and vision evaluation every year.
- Repeat cervical spine x-rays if needed.
- Echocardiogram if evidence of valvular disease on clinical exam.

Adults (over 18 years):
- Annual thyroid screening.
- Ophthalmologic evaluation every 2 years.
- Repeat cervical spine x-rays as needed.
- Auditory testing every 2 years.
- Twice yearly dental visits.
- Pap smears every 1-3 year following the age of first intercourse.
- For women who are sexually not active, finger- directed cytology exam.
- Screening pelvic ultrasound every 2-3 years for women who refuse or have inadequate follow -up bimanual examinations.
- Yearly breast examination.
- Mammography after age 50.

Prenatal Screening
Because of the morbidity associated with Down syndrome, screening and diagnostic testing for this condition are offered as optional components of prenatal care. Prenatal diagnosis of trisomy 21 allows parents the choice of continuing or terminating an affected pregnancy.

The incidence of fetal trisomies is directly related to maternal age. The risk of having a child with Down syndrome increases in a gradual, linear fashion until about age 30 and increases exponentially thereafter (2). The risk of having a child with Down syndrome is 1/1300 for a 25-year old woman; at age 35, the risk increases to 1/365. At age 45, the risk of having a child increases to 1/30.

If a patient has had a trisomy 21 pregnancy in the past, the risk of recurrence in a subsequent pregnancy is still highly dependent on maternal age. If the previously affected pregnancy was a chromosome-21 translocation the recurrence risk is high enough to dwarf the age- specific risk at most ages.

Maternal serum screening: Maternal serum screening can allow the detection of trisomy 21 pregnancies in women in younger than 35 years who give birth to about 70 percent of infants with Down syndrome. The serum markers most widely used are:
- Alfa-fetoprotein
- Unconjugated estriol
- Human chorionic gonadotropin
- Inhibin A
This combination is known as "quadruple test" or "triple test" (without Inhibin A). The maternal serum levels of these proteins and of steroid hormones vary with the gestational age for the pregnancy. These test are usually performed at 15 to 18 weeks of gestation. The level of each serum marker is measured and reported as a multiple of the median for women with pregnancies of the same gestational age as that of the patient's. The likelihood of trisomy 21 is calculated on the basis of each of the serum marker results and the patient's age. A positive test is an indication for amniocentesis.

The triple test can detect 60 percent of trisomy 21 pregnancies; it has a false-positive rate of 5 percent. The likelihood of fetus having trisomy 21 in a patient with a positive test is about 2 percent. A normal result reduces the likelihood of trisomy 21 but does not exclude it. Test performance can be slightly improved by adjusting for maternal weight, ethnic group and insulin-dependent diabetes mellitus. The triple test fails to detect 10 to 15 percent of trisomy 21 pregnancies in older age group. Therefore for women 35 years or older, maternal serum screening should not be offered as an equivalent alternative to amniocentesis or chorionic villus sampling. Several demographic or pregnancy-related factors influence the biochemical levels. Taking these factors into account will enhance screening performance. The factors are:
- Gestational age
- Maternal weight
- Maternal race
- Maternal insulin-dependant diabetes
- Multiple fetal pregnancy
- Family history of Down syndrome

Ultrasound Assessment
An estimate of gestational age by ultrasonography improves the performance of the triple or quadruple test. Second-trimester ultrasound assessment may be helpful for predicting the likelihood of trisomy 21 in pregnancies at increased risk. Ultrasonographic findings associated with fetal Down syndrome :
- Increased nuchal fold thickness >5 mm
- Intrauterine growth restriction
- Mild cerebral ventriculomegaly
- Brachycephaly
- Flat facies
- Small ears
- Choroid plexus cysts
- Cystic hygromas
- Echogenic intracardiac foci
- Congenital heart defects
- Ventricular septal defect
- Atrio-ventricular canal
- Tetralogy of Fallot
- Bright papillary muscle
- Increased intestinal echogenicity
- Duodenal atresia ("double -bubble sign") after 22 weeks' gestation
- Renal pelvis dilation
- Shortened humerus and femur
- Increased iliac wing angle
- Incurving (clinodactyly) and hypoplasia of the fifth finger
- Increased space between first and second toes
- Two-vessel umbilical cord
- Non-immune hydrops
- Possible increased biparietal diameter-femur length ratio

FIRST-TRIMESTER SCREENING: First-trimester screening by means of maternal age and measurement of nuchal translucency could provide a trisomy 21 detection rate of 63 percent, with a 5 percent false-positive rate. Combining this with measurement of maternal serum free beta-hCG subunit and pregnancy associated protein A could increase the detection rate to 80 percent, at the same false- positive rate.

Definitive prenatal diagnosis of trisomy 21 requires cytogenetic analysis of cells obtained by one of the three invasive procedures:
- Chorionic villus sampling
- Early amniocentesis
- Second-trimester amniocentesis

Chorionic villus sampling (CVS) and early amniocentesis are the primary diagnostic procedures used between 11 and 14 weeks gestation. The risks of amniocentesis include
- Rare puncture of the fetus
- Bleeding
- Infection
- Isosensitization
- Neonatal respiratory distress syndrome
- Neonatal pneumonia

The risk of CVS include:
- Limb reduction defects
- Bleeding
However if CVS is done at 10 weeks or later the incidence of fetal defects is reduced.


Contributor Information and Disclosures

Swati Kolpuru
Consultant Pediatrician, USA

First Created : 12/24/2001
Last Updated : 8/1/2015


Advertisements by :    Mega-CV by Aristo IndoIV by Sun Pharma
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.